Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Better Buy: Amgen vs. Celgene

TheMotleyFool

0 0

Amgen (NASDAQ: AMGN) is about to get a piece of Celgene (NASDAQ: CELG). Sort of. To ease the way for the pending acquisition of Celgene by Bristol-Myers Squibb (NYSE: BMY) to close, Celgene is selling its psoriasis and psoriatic drug Otezla to Amgen for a cool $13.4 billion. It's a win-win-win deal.

But with all of the shuffling going on, which of these two big biotechs -- Amgen or Celgene -- is the better pick for investors hoping to win? The answer: It's complicated.

Image source: Getty Images.

Source Fool.com

Like: 0

CELG

Share